Ortho-McNeil Pharmaceutical, Inc.

40 articles about Ortho-McNeil Pharmaceutical, Inc.

• Ortho-McNeil Pharmaceutical, Inc. Ditches $625 Million Diabetes Drug Pact with Diamyd Medical AB

  6/2/2011

• Ortho-McNeil Pharmaceutical, Inc. Enters into Agreement with Watson Laboratories, Inc. for CONCERTA(R) Authorized Generic

  11/2/2010

• Metabolex, Inc. Enters Into Type 2 Diabetes Development and License Agreement with Ortho-McNeil Pharmaceutical, Inc.; Metabolex Could be Eligible to Receive Development, Regulatory, and Commercial Milestones up to $330 Million

  6/22/2010

• Ortho-McNeil Pharmaceutical, Inc. Pleads Guilty to Illegal Promotion of Topamax and is Sentenced to Criminal Fine of $6.14 Million

  5/24/2010

• Ortho-McNeil Pharmaceutical, Inc. Resolves Investigation of Past TOPAMAX(R) Marketing and Promotional Activities

  4/29/2010

• FDA Issues Complete Response Letter for Ortho-McNeil Pharmaceutical, Inc.'s Rivaroxaban

  5/28/2009

• Ortho-McNeil Pharmaceutical, Inc. New Study Supports Use of LEVAQUIN as a Guideline-Concordant Antibiotic for the Treatment of Community-Acquired Pneumonia

  10/27/2008

• Isis Pharmaceuticals, Inc.Announces HSR Approval and Closure of Its Collaboration With Ortho-McNeil Pharmaceutical, Inc.

  10/2/2007

• FDA Approves Ortho-McNeil Pharmaceutical, Inc.'s LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis

  9/17/2007

• Isis Pharmaceuticals, Inc. Licenses Experimental Diabetes Drugs to Ortho-McNeil Pharmaceutical, Inc. for $45 Million

  9/13/2007

• Bristol-Myers Squibb Company Release: Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin in Complicated Urinary Tract Infections and Acute Pyelonephritis

  5/21/2007

• Ortho-McNeil Pharmaceutical, Inc. Data Show Low Incidence of Breakthrough Bleeding With ORTHO TRI-CYCLEN(R) LO In a Broad Range of Women

  5/9/2007

• The Day In Review: Entereg from GlaxoSmithKline and Adolor Corporation Fails Test

  4/10/2007

• The Day In Review: NPS Pharmaceuticals, Inc. Cuts Staff Again

  3/15/2007

• FDA Extends Ortho-McNeil Pharmaceutical, Inc. Marketing Exclusivity for LEVAQUIN(R)

  3/15/2007

• Cellzome AG Receives First Milestone Payment for Alzheimer's Program from Ortho-McNeil Pharmaceutical, Inc.

  3/13/2007

• Women Sue Over Birth Control Patch

  11/2/2006

• The Day In Review: Amgen Gets Approval For Vectibix

  9/27/2006

• Arena Pharmaceuticals, Inc. Announces That Ortho-McNeil Pharmaceutical, Inc. Extends Research Term Under Partnership To Develop Drugs To Treat Type 2 Diabetes

  9/27/2006

• Ortho-McNeil Pharmaceutical, Inc.'s Birth-Control Patch Label Warns Of Risk

  9/20/2006